Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jason Bacharach, Iqbal Ike K Ahmed, Elizabeth D Sharpe, Michael S Korenfeld, Steven Zhang & Christophe Baudouin. (2023) Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial. Clinical Ophthalmology 17, pages 2575-2588.
Read now
Read now
Michele Figus, Luca Agnifili, Manuela Lanzini, Lorenza Brescia, Francesco Sartini, Leonardo Mastropasqua & Chiara Posarelli. (2021) Topical preservative-free ophthalmic treatments: an unmet clinical need. Expert Opinion on Drug Delivery 18:6, pages 655-672.
Read now
Read now
Daisuke Inoue, Yasser Helmy Mohamed, Masafumi Uematsu & Takashi Kitaoka. (2020) Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops. Cutaneous and Ocular Toxicology 39:2, pages 158-164.
Read now
Read now
Jose M Martinez-de-la-Casa, Shaantanu Donde & Joanna Wierzbowska. (2019) Latanoprost, a balanced prostaglandin. Expert Review of Ophthalmology 14:1, pages 61-72.
Read now
Read now
Mario A Economou, Helene Kolstad Laukeland, Iwona Grabska-Liberek & Jean-François Rouland. (2018) Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. Clinical Ophthalmology 12, pages 2399-2407.
Read now
Read now
Articles from other publishers (14)
Anne Hedengran Nagstrup. (2023) The use of benzalkonium chloride in topical glaucoma treatment. Acta Ophthalmologica 101:S278, pages 3-21.
Crossref
Crossref
Anne Hedengran & Miriam Kolko. (2023) Controversial preservation of eye drops: the toxicity of benzalkonium chloride. Adverse Drug Reaction Bulletin 338:1, pages 1311-1314.
Crossref
Crossref
Nupur Vasdev, Nakshatra Chaudhari, Suryanarayana Polaka, Kuldeep Rajpoot, Piyush Gondaliya, Adil Ali Sayyed, Pinaki Sengupta & Rakesh Kumar Tekade. (2023) Current progress in preservative-free topical ophthalmic formulations. Journal of Drug Delivery Science and Technology 79, pages 103996.
Crossref
Crossref
Fredrik Fineide, Neil Lagali, Muhammed Yasin Adil, Reiko Arita, Miriam Kolko, Jelle Vehof & Tor P. Utheim. (2022) Topical glaucoma medications – Clinical implications for the ocular surface. The Ocular Surface 26, pages 19-49.
Crossref
Crossref
Anna-Sophie Thein, Anne Hedengran, Augusto Azuara-Blanco, Reiko Arita, Barbara Cvenkel, Gus Gazzard, Steffen Heegaard, Cintia S. de Paiva, Goran Petrovski, Verena Prokosch-Willing, Tor P. Utheim, Gianni Virgili & Miriam Kolko. (2022) Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)—A Delphi Consensus Statement. American Journal of Ophthalmology 241, pages 190-197.
Crossref
Crossref
Anne Guldhammer Skov, Amalie Santaolalla Rives, Josefine Freiberg, Gianni Virgili, Augusto Azuara‐Blanco & Miriam Kolko. (2021) Comparative efficacy and safety of preserved versus preservative‐free beta‐blockers in patients with glaucoma or ocular hypertension: a systematic review. Acta Ophthalmologica 100:3, pages 253-261.
Crossref
Crossref
Olivia Müllertz, Anne Hedengran, Zaynab Ahmad Mouhammad, Josefine Freiberg, Richárd Nagymihály, Jette Jacobsen, Susan Weng Larsen, Jeffrey Bair, Tor P Utheim, Darlene A Dartt, Steffen Heegaard, Goran Petrovski & Miriam Kolko. (2021) Impact of benzalkonium chloride-preserved and preservative-free latanoprost eye drops on cultured human conjunctival goblet cells upon acute exposure and differences in physicochemical properties of the eye drops. BMJ Open Ophthalmology 6:1, pages e000892.
Crossref
Crossref
Joon Mo Kim, Sang Woo Park, Mincheol Seong, Seung Joo Ha, Ji Woong Lee, Seungsoo Rho, Chong Eun Lee, Kyoung Nam Kim, Tae-Woo Kim, Kyung Rim Sung & Chan Yun Kim. (2021) Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost. Pharmaceuticals 14:6, pages 501.
Crossref
Crossref
Stephanie H. Choi, Yan Wang & Darby Kozak. 2021. Ophthalmic Product Development. Ophthalmic Product Development
571
590
.
Song Min Lee & Sang Wook Jin. (2020) Efficacy of Preservative-free Latanoprost in Normal-tension Glaucoma with Mild to Moderate Dry Eye. Journal of the Korean Ophthalmological Society 61:6, pages 639-644.
Crossref
Crossref
Yong Woo KimSeung Chan LeeSeoyoung WyEunoo Bak. (2020) Efficacy and Patient Tolerability of Preservative-free Latanoprost in Korean Primary Open Angle Glaucoma Patients. Journal of the Korean Glaucoma Society 9:1, pages 10.
Crossref
Crossref
Florent Aptel, Norbert Pfeiffer, Stefanie Schmickler, Jonathan Clarke, Cosme Lavín-Dapena, Javier Moreno-Montañés, Tomasz Żarnowski, Adrienne Csutak, Tiia Jugaste, Lāsma Volksone, Yury S. Astakhov, Laurent Coupier, Jean-Philippe Nordmann & Ingeborg Stalmans. (2019) Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension. Journal of Glaucoma 28:6, pages 498-506.
Crossref
Crossref
Jose M. Martinez-de-la-Casa, Francisco Perez-Bartolome, Elena Urcelay, Jose L. Santiago, Javier Moreno-Montañes, Pedro Arriola-Villalobos, Jose M. Benitez-del-Castillo & Julian Garcia-Feijoo. (2017) Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost. The Ocular Surface 15:4, pages 723-729.
Crossref
Crossref
Yury S Astakhov & Pavel A Nechiporenko. (2017) Prostaglandin analogues: past, present, and future. Ophthalmology Reports 10:1, pages 40-52.
Crossref
Crossref